HOOKIPA Pharma Inc. (HOOK) |
|
0.736 0.016 (2.18%)
|
03-31 16:00 |
|
Open: |
0.74 |
Pre. Close: |
0.7203 |
|
High:
|
0.74 |
Low:
|
0.7 |
|
Volume:
|
160,291 |
Market Cap:
|
41(M) |
|
|
|
Technical analysis |
as of: 2023-03-31 4:19:22 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 0.99  One year: 1.1 |
| Support: |
Support1: 0.69 Support2: 0.58 |
| Resistance: |
Resistance1: 0.85 Resistance2: 0.94 |
| Pivot: |
0.77 |
| Moving Average: |
MA(5): 0.73 MA(20): 0.8
MA(100): 0.91 MA(250): 1.28 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 12.3 %D(3): 9.9 |
| RSI: |
RSI(14): 33.9 |
| 52-week: |
High: 2.2 Low: 0.69 |
| Average Vol(K): |
3-Month: 185 (K) 10-Days: 152 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ HOOK ] has closed above bottom band by 22.5%. Bollinger Bands are 22.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.75 - 0.76 |
0.76 - 0.76 |
|
Low:
|
0.71 - 0.71 |
0.71 - 0.72 |
|
Close:
|
0.71 - 0.72 |
0.72 - 0.73 |
|
Company Description |
|
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York. |
Headline News |
Sat, 18 Mar 2023
HOOKIPA Pharma Inc. (NASDAQ:HOOK) Q4 2022 Earnings Call Transcript - Yahoo Finance
Fri, 17 Mar 2023
HOOKIPA Pharma Full Year 2022 Earnings: Beats Expectations - Yahoo Finance
Thu, 16 Mar 2023
Short Volatility Alert: Hookipa Pharma Inc - HOOKIPA Pharma ... - Benzinga
Tue, 14 Mar 2023
Pre-Market Earnings Report for March 15, 2023 : GDS, CLMT, OTLY ... - Nasdaq
Mon, 13 Mar 2023
HOOKIPA Pharma Appoints Terry Coelho to its Board of Directors - GlobeNewswire
Mon, 13 Feb 2023
HOOKIPA Achieves $10 Million Milestone Payment in Development ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
52 (M) |
| Shares Float |
39 (M) |
|
% Held by Insiders
|
8.1 (%) |
|
% Held by Institutions
|
53.6 (%) |
|
Shares Short
|
186 (K) |
|
Shares Short P.Month
|
137 (K) |
Stock Financials |
|
EPS
|
-1.6 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
2.06 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-513.5 |
|
Return on Assets (ttm)
|
0 |
|
Return on Equity (ttm)
|
-64 |
|
Qtrly Rev. Growth
|
101 |
|
Gross Profit (p.s.)
|
-1.04 |
|
Sales Per Share
|
0.27 |
|
EBITDA (p.s.)
|
-1.33 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
-0.47 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
0.35 |
|
Price to Sales
|
2.7 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
